Regenerating gene type IV and cytokeratin 18 in the patients with advanced gastric cancer: expression and clinical significance

W. Deng,Xiaotian Zhang,Jing Gao,L. Shen
2012-01-12
Abstract:Objective  To explore the expression of two serum markers, namely regenerating gene type Ⅳ (REG Ⅳ, also named "regenerating islet-derived family, member 4") and cytokeratin 18 (CK18), and evaluate the correlation between REG Ⅳ and CK18, and their value in monitoring the effect of chemotherapy in patients with advanced gastric cancer. Methods  As a retrospective study, the in-patients with advanced gastric cancer treated at the gastrointestinal medical department of Beijing Cancer Hospital and a cohort of healthy individuals were included. Peripheral venous blood was collected, and ELISA quantitative analysis was used to determine the serum levels of REG Ⅳ and CK18 in patients with gastric cancer before and after chemotherapy and also healthy controls. Results  Compared with healthy control individuals (n=32), patients with gastric cancer (n=61) showed significantly (P 0.05). The response to the combined chemotherapy among 36 patients who had matched serum for examination after chemotherapy was as follows: 14 patients were in chemotherapy-sensitive group (CR+PR), 16 patients with stable disease (SD), and 6 patients showed progressive disease (PD). There was no change in REG Ⅳ and CK18 before and after chemotherapy for predicting the outcome of the patients (P>0.05). Conclusion Compared with healthy control individuals, patients with gastric cancer showed significantly increased REG Ⅳ and CK-18 levels in the serum. No association was found between REG Ⅳ and CK18 levels and response to chemotherapy. Changes in REG Ⅳ and CK18 before or after chemotherapy were not found significant in predicting the treatment result of the patients.
Medicine
What problem does this paper attempt to address?